The EC approval is a major regulatory milestone but the stock's reaction will depend on the PREVAIL interim analysis result expected in Q1 2027, which is the key catalyst for obicetrapib's cardiovascular outcomes data. Monitor Menarini's European launch execution and the RUBENS Phase 3 top-line data expected around year-end 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $20.93entry
- T+1 · 12d ago −9.75%α −5.34% · $18.89
- T+5 · 6d ago −1.00%α −0.09% · $20.72
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NewAmsterdam Pharma reported Q3 2026 net loss of $17.4M, significantly narrower than the $72.0M loss in Q3 2025, driven by a $23.1M non-cash gain on warrant revaluation and $19.2M in revenue from Menarini regulatory milestones. The company received European Commission approval for obicetrapib (Ubeslo and Evlarco), its first regulatory approval worldwide, and initiated the SPINOZA Phase 2b Alzheimer's trial. Cash stood at $643.1M at quarter-end.
Key Financial Metrics
Key Facts
- European Commission granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe FDC) in September 2026, the first regulatory approval of obicetrapib worldwide
- Net loss of $17.4M in Q3 2026 vs $72.0M in Q3 2025, improvement driven by $23.1M non-cash gain on warrant fair value change and $19.2M in revenue from Menarini regulatory milestones
- Revenue of $19.2M in Q3 2026 vs $0.3M in Q3 2025, entirely from milestone recognition under the Menarini license agreement
- Cash, cash equivalents and marketable securities of $643.1M at September 30, 2026, down from $728.9M at December 31, 2025
- PREVAIL cardiovascular outcomes trial interim analysis planned for Q4 2026 with result expected in Q1 2027
- Menarini plans to launch Ubeslo and Evlarco in Germany by YE2026 and UK in 2027
- SPINOZA Phase 2b trial in preclinical Alzheimer's disease initiated in September 2026
Financial Impact
Net loss improved by $54.6M YoY; revenue increased by $18.9M; cash burn of $85.8M in 9M 2026; EPS beat consensus by $0.30
Risk Factors
- PREVAIL interim analysis outcome is binary and could significantly impact the stock
- No product revenue yet; company relies on milestone payments and partnership royalties
- Cash burn rate of ~$85M per nine months suggests runway of approximately 2 years at current spend
- European commercial launch depends on Menarini's execution and pricing/reimbursement decisions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395208 |
Track record
8 reports on NAMS
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
- Nov 4, 202612d ago Press Release Neutral 5/10 Viewing Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
- Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
- Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
- Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
- Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers